quinazolines has been researched along with Adenocarcinoma, Scirrhous in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aono, T; Iwase, K; Nakamura, Y; Nomura, M; Tanaka, Y | 1 |
| Date, M; Fujise, K; Matsumoto, K; Nakamura, T; Namiki, T; Namiki, Y; Satoi, J; Tada, N; Yanagihara, K; Yashiro, M; Yoshida, H | 1 |
2 other study(ies) available for quinazolines and Adenocarcinoma, Scirrhous
| Article | Year |
|---|---|
[Two cases of HER2-positive advanced or metastatic breast cancer, responding to lapatinib and capecitabine].
Topics: Adenocarcinoma, Scirrhous; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Lung Neoplasms; Lymph Node Excision; Mastectomy; Middle Aged; Quinazolines; Receptor, ErbB-2 | 2010 |
Preclinical study of a "tailor-made" combination of NK4-expressing gene therapy and gefitinib (ZD1839, Iressa) for disseminated peritoneal scirrhous gastric cancer.
Topics: Adenocarcinoma, Scirrhous; Administration, Oral; Adult; Animals; Antineoplastic Agents; Cell Line; Cell Line, Tumor; Cell Proliferation; Cytokines; Dose-Response Relationship, Drug; ErbB Receptors; Gefitinib; Genetic Therapy; Hepatocyte Growth Factor; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Peritoneum; Quinazolines; Stomach Neoplasms; Survival Analysis; Treatment Outcome; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2006 |